Evaluation of the performance of a lateral flow device for quantitative detection of anti-SARS-CoV-2 IgG
Introduction: The AbC-19™ lateral flow immunoassay (LFIA) performance was evaluated on plasma samples from a SARS-CoV-2 vaccination cohort, WHO international standards for anti-SARS-CoV-2 IgG (human), individuals ≥2 weeks from infection of RT-PCR confirmed SARS-CoV-2 genetic variants, as well as mic...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-12-01
|
| Series: | Clinical Immunology Communications |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S277261342200021X |
| _version_ | 1798000523132010496 |
|---|---|
| author | J.S. Moore L.J. Robertson R. Price G. Curry J. Farnan A. Black M.A. Nesbit J.A. McLaughlin T. Moore |
| author_facet | J.S. Moore L.J. Robertson R. Price G. Curry J. Farnan A. Black M.A. Nesbit J.A. McLaughlin T. Moore |
| author_sort | J.S. Moore |
| collection | DOAJ |
| description | Introduction: The AbC-19™ lateral flow immunoassay (LFIA) performance was evaluated on plasma samples from a SARS-CoV-2 vaccination cohort, WHO international standards for anti-SARS-CoV-2 IgG (human), individuals ≥2 weeks from infection of RT-PCR confirmed SARS-CoV-2 genetic variants, as well as microorganism serology.Methods: Pre-vaccination to three weeks post-booster samples were collected from a cohort of 111 patients (including clinically extremely vulnerable patients) from Northern Ireland. All patients received Oxford-AstraZeneca COVID-19 vaccination for the first and second dose, and Pfizer-BioNTech for the third (first booster). WHO international standards, 15 samples from 2 variants of concern (Delta and Omicron) and cross-reactivity with plasma samples from other microorganism infections were also assessed on AbC-19™.Results: All 80 (100%) participants sampled post-booster had high positive IgG responses, compared to 38/95 (40%) participants at 6 months post-first vaccination. WHO standard results correlated with information from corresponding biological data sheets, and antibodies to all genetic variants were detected by LFIA. No cross-reactivity was found with exception of one (of five) Dengue virus samples.Conclusion: These findings suggest BNT162b2 booster vaccination enhanced humoral immunity to SARS-CoV-2 from pre-booster levels, and that this antibody response was detectable by the LFIA. In combination with cross-reactivity, standards and genetic variant results would suggest LFIA may be a cost-effective measure to assess SARS-CoV-2 antibody status. |
| first_indexed | 2024-04-11T11:21:38Z |
| format | Article |
| id | doaj.art-5f42854277d64c7e8b1a9c85d7aa5965 |
| institution | Directory Open Access Journal |
| issn | 2772-6134 |
| language | English |
| last_indexed | 2024-04-11T11:21:38Z |
| publishDate | 2022-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Clinical Immunology Communications |
| spelling | doaj.art-5f42854277d64c7e8b1a9c85d7aa59652022-12-22T04:27:02ZengElsevierClinical Immunology Communications2772-61342022-12-012130135Evaluation of the performance of a lateral flow device for quantitative detection of anti-SARS-CoV-2 IgGJ.S. Moore0L.J. Robertson1R. Price2G. Curry3J. Farnan4A. Black5M.A. Nesbit6J.A. McLaughlin7T. Moore8Biomedical Sciences Research Institute, Ulster University, Northern Ireland, United Kingdom; Integrated Diagnostics Laboratory, Ulster University, 3-5a Frederick St, Belfast, Northern Ireland, United KingdomBiomedical Sciences Research Institute, Ulster University, Northern Ireland, United Kingdom; Integrated Diagnostics Laboratory, Ulster University, 3-5a Frederick St, Belfast, Northern Ireland, United KingdomBiomedical Sciences Research Institute, Ulster University, Northern Ireland, United KingdomBiomedical Sciences Research Institute, Ulster University, Northern Ireland, United Kingdom; Integrated Diagnostics Laboratory, Ulster University, 3-5a Frederick St, Belfast, Northern Ireland, United KingdomThe Group Surgery, 257 North Queen Street, Belfast, Northern Ireland, United KingdomThe Group Surgery, 257 North Queen Street, Belfast, Northern Ireland, United KingdomBiomedical Sciences Research Institute, Ulster University, Northern Ireland, United Kingdom; Integrated Diagnostics Laboratory, Ulster University, 3-5a Frederick St, Belfast, Northern Ireland, United KingdomIntegrated Diagnostics Laboratory, Ulster University, 3-5a Frederick St, Belfast, Northern Ireland, United Kingdom; Nanotechnology and Integrated Bioengineering Centre, Ulster University, Northern Ireland, United KingdomBiomedical Sciences Research Institute, Ulster University, Northern Ireland, United Kingdom; Integrated Diagnostics Laboratory, Ulster University, 3-5a Frederick St, Belfast, Northern Ireland, United Kingdom; Corresponding author at: Biomedical Sciences Research Institute, Ulster University, Northern Ireland, United Kingdom.Introduction: The AbC-19™ lateral flow immunoassay (LFIA) performance was evaluated on plasma samples from a SARS-CoV-2 vaccination cohort, WHO international standards for anti-SARS-CoV-2 IgG (human), individuals ≥2 weeks from infection of RT-PCR confirmed SARS-CoV-2 genetic variants, as well as microorganism serology.Methods: Pre-vaccination to three weeks post-booster samples were collected from a cohort of 111 patients (including clinically extremely vulnerable patients) from Northern Ireland. All patients received Oxford-AstraZeneca COVID-19 vaccination for the first and second dose, and Pfizer-BioNTech for the third (first booster). WHO international standards, 15 samples from 2 variants of concern (Delta and Omicron) and cross-reactivity with plasma samples from other microorganism infections were also assessed on AbC-19™.Results: All 80 (100%) participants sampled post-booster had high positive IgG responses, compared to 38/95 (40%) participants at 6 months post-first vaccination. WHO standard results correlated with information from corresponding biological data sheets, and antibodies to all genetic variants were detected by LFIA. No cross-reactivity was found with exception of one (of five) Dengue virus samples.Conclusion: These findings suggest BNT162b2 booster vaccination enhanced humoral immunity to SARS-CoV-2 from pre-booster levels, and that this antibody response was detectable by the LFIA. In combination with cross-reactivity, standards and genetic variant results would suggest LFIA may be a cost-effective measure to assess SARS-CoV-2 antibody status.http://www.sciencedirect.com/science/article/pii/S277261342200021XSARS-CoV-2Lateral flow immunoassayAntibodyVaccineVariant |
| spellingShingle | J.S. Moore L.J. Robertson R. Price G. Curry J. Farnan A. Black M.A. Nesbit J.A. McLaughlin T. Moore Evaluation of the performance of a lateral flow device for quantitative detection of anti-SARS-CoV-2 IgG Clinical Immunology Communications SARS-CoV-2 Lateral flow immunoassay Antibody Vaccine Variant |
| title | Evaluation of the performance of a lateral flow device for quantitative detection of anti-SARS-CoV-2 IgG |
| title_full | Evaluation of the performance of a lateral flow device for quantitative detection of anti-SARS-CoV-2 IgG |
| title_fullStr | Evaluation of the performance of a lateral flow device for quantitative detection of anti-SARS-CoV-2 IgG |
| title_full_unstemmed | Evaluation of the performance of a lateral flow device for quantitative detection of anti-SARS-CoV-2 IgG |
| title_short | Evaluation of the performance of a lateral flow device for quantitative detection of anti-SARS-CoV-2 IgG |
| title_sort | evaluation of the performance of a lateral flow device for quantitative detection of anti sars cov 2 igg |
| topic | SARS-CoV-2 Lateral flow immunoassay Antibody Vaccine Variant |
| url | http://www.sciencedirect.com/science/article/pii/S277261342200021X |
| work_keys_str_mv | AT jsmoore evaluationoftheperformanceofalateralflowdeviceforquantitativedetectionofantisarscov2igg AT ljrobertson evaluationoftheperformanceofalateralflowdeviceforquantitativedetectionofantisarscov2igg AT rprice evaluationoftheperformanceofalateralflowdeviceforquantitativedetectionofantisarscov2igg AT gcurry evaluationoftheperformanceofalateralflowdeviceforquantitativedetectionofantisarscov2igg AT jfarnan evaluationoftheperformanceofalateralflowdeviceforquantitativedetectionofantisarscov2igg AT ablack evaluationoftheperformanceofalateralflowdeviceforquantitativedetectionofantisarscov2igg AT manesbit evaluationoftheperformanceofalateralflowdeviceforquantitativedetectionofantisarscov2igg AT jamclaughlin evaluationoftheperformanceofalateralflowdeviceforquantitativedetectionofantisarscov2igg AT tmoore evaluationoftheperformanceofalateralflowdeviceforquantitativedetectionofantisarscov2igg |